

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

Histone H3 (K27M Mutant Specific) (D3B5T) Rabbit mAb

RRID:AB_2799861

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 74829, RRID:AB_2799861

Antibody Information

URL: http://antibodyregistry.org/AB_2799861

Proper Citation: Cell Signaling Technology Cat# 74829, RRID:AB_2799861

Target Antigen: H3F3A

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC

Antibody Name: Histone H3 (K27M Mutant Specific) (D3B5T) Rabbit mAb

Description: This monoclonal targets H3F3A

Target Organism: h, m

Clone ID: Clone D3B5T

Antibody ID: AB_2799861

Vendor: Cell Signaling Technology

Catalog Number: 74829

Record Creation Time: 20250820T035151+0000

Record Last Update: 20250820T172312+0000

Ratings and Alerts

No rating or validation information has been found for Histone H3 (K27M Mutant Specific) (D3B5T) Rabbit mAb.

No alerts have been found for Histone H3 (K27M Mutant Specific) (D3B5T) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mason MS, et al. (2026) Modeling diffuse midline glioma through triple-electrode in utero electroporation of the developing mouse pons. PloS one, 21(6), e0351079.

Erez N, et al. (2025) Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline glioma. Cell reports. Medicine, 6(1), 101918.

Sun H, et al. (2023) Recruitment of TRIM33 to cell-context specific PML nuclear bodies regulates nodal signaling in mESCs. The EMBO journal, 42(3), e112058.

Furth N, et al. (2022) H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape. Cell reports, 39(7), 110836.

Harpaz N, et al. (2022) Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. Molecular cell, 82(14), 2696.

Ehteda A, et al. (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell reports, 35(2), 108994.